

Inge C Van Gool

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7281258/publications.pdf>

Version: 2024-02-01

13
papers

1,445
citations

840776

11
h-index

1125743

13
g-index

13
all docs

13
docs citations

13
times ranked

3240
citing authors

#	ARTICLE	IF	CITATIONS
1	Antineutrophil cytoplasmic antibodies in infective endocarditis: a case report and systematic review of the literature. <i>Clinical Rheumatology</i> , 2022, 41, 2949-2960.	2.2	9
2	A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression. <i>Modern Pathology</i> , 2020, 33, 2128-2138.	5.5	378
3	A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer. <i>Cancer Immunology Research</i> , 2019, 7, 784-796.	3.4	141
4	Somatic <i>POLE</i> exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response. <i>Journal of Pathology</i> , 2018, 245, 283-296.	4.5	71
5	Adjuvant Treatment for <i>POLE</i> Proofreading Domainâ€“Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues. <i>Clinical Cancer Research</i> , 2018, 24, 3197-3203.	7.0	50
6	Blinded histopathological characterisation of <i>POLE</i> exonuclease domain mutant endometrial cancers: sheep in wolf's clothing. <i>Histopathology</i> , 2018, 72, 248-258.	2.9	34
7	Immunological profiling of molecularly classified high-risk endometrial cancers identifies <i>POLE</i> -mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. <i>Oncotarget</i> , 2017, 8, e1264565.	4.6	102
8	Limited impact of intratumour heterogeneity on molecular risk assignment in endometrial cancer. <i>Oncotarget</i> , 2017, 8, 25542-25551.	1.8	15
9	Neopeptides and CD3-Positive and CD8-Positive Cells in Polymerase â€“Mutated and Microsatellite-Unstable Endometrial Cancers. <i>JAMA Oncology</i> , 2016, 2, 141.	7.1	2
10	A panoply of errors: polymerase proofreading domain mutations in cancer. <i>Nature Reviews Cancer</i> , 2016, 16, 71-81.	28.4	292
11	Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer. <i>Modern Pathology</i> , 2016, 29, 174-181.	5.5	68
12	<i>POLE</i> proofreading mutation, immune response and prognosis in endometrial cancer. <i>Oncotarget</i> , 2016, 7, e1072675.	4.6	34
13	<i>POLE</i> Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 3347-3355.	7.0	249